A detailed history of Black Rock Inc. transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 5,701,905 shares of STRO stock, worth $16.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,701,905
Previous 5,823,922 2.1%
Holding current value
$16.7 Million
Previous $25 Million 28.94%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$3.27 - $5.65 $398,995 - $689,396
-122,017 Reduced 2.1%
5,701,905 $32.2 Million
Q4 2023

Feb 13, 2024

SELL
$2.07 - $4.54 $336,743 - $738,558
-162,678 Reduced 2.72%
5,823,922 $25 Million
Q3 2023

Nov 13, 2023

SELL
$3.29 - $4.9 $62,368 - $92,889
-18,957 Reduced 0.32%
5,986,600 $20.8 Million
Q2 2023

Aug 11, 2023

BUY
$4.25 - $5.88 $4.19 Million - $5.79 Million
984,734 Added 19.61%
6,005,557 $27.9 Million
Q1 2023

May 12, 2023

BUY
$4.48 - $8.45 $719,859 - $1.36 Million
160,683 Added 3.31%
5,020,823 $23.2 Million
Q4 2022

Feb 13, 2023

BUY
$5.41 - $8.08 $4.61 Million - $6.88 Million
851,770 Added 21.25%
4,860,140 $39.3 Million
Q3 2022

Nov 14, 2022

BUY
$5.17 - $7.11 $1.48 Million - $2.03 Million
285,745 Added 7.68%
4,008,370 $22.2 Million
Q2 2022

Aug 12, 2022

SELL
$3.41 - $8.95 $21,155 - $55,525
-6,204 Reduced 0.17%
3,722,625 $19.4 Million
Q1 2022

May 12, 2022

BUY
$7.78 - $15.31 $223,955 - $440,713
28,786 Added 0.78%
3,728,829 $30.7 Million
Q4 2021

Feb 10, 2022

BUY
$14.25 - $23.53 $620,815 - $1.03 Million
43,566 Added 1.19%
3,700,043 $55.1 Million
Q3 2021

Nov 09, 2021

BUY
$16.88 - $22.38 $500,964 - $664,193
29,678 Added 0.82%
3,656,477 $69.1 Million
Q2 2021

Aug 11, 2021

BUY
$18.03 - $23.82 $65.4 Million - $86.4 Million
3,626,799 New
3,626,799 $67.4 Million

Others Institutions Holding STRO

About SUTRO BIOPHARMA, INC.


  • Ticker STRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,161,500
  • Market Cap $153M
  • Description
  • Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...
More about STRO
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.